Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis

Pediatric Pulmonology

Volumn 48, Issue 3, 2013, Pages 229-235

  Cohen Cymberknoh, Malena ^a   Yaakov, Yasmin ^a   Shoseyov, David ^a   Shteyer, Eyal ^a   Schachar, Edna ^a   Rivlin, Joseph ^b   Bentur, Lea ^c   Picard, Elie ^d   Aviram, Micha ^e   Israeli, Eran ^a   Kerem, Eitan ^a   Wilschanski, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c MEYER CHILDREN S HOSPITAL   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

cystic fibrosis; ion transport; rectal biopsy

Indexed keywords

CARBACHOL; CYCLIC AMP; FORSKOLIN; HISTAMINE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EVALUATION; GENETIC ANALYSIS; HUMAN; INTESTINAL CURRENT MEASUREMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECTUM BIOPSY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; STATISTICAL MODEL; SWEAT TEST;

ADOLESCENT; ADULT; BIOPSY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHLORIDE CHANNELS; CYSTIC FIBROSIS; ELECTRODIAGNOSIS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; POTASSIUM CHANNELS; RECTUM; ROC CURVE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84874117123     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22586     Document Type: Article

References (35)

1. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr 2008; 153: S4-S14.
2. Wilschanski M, Durie P,. Patterns of gastrointestinal disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56: 1153-1163.
3. Rosenstein MR, Cutting GR,. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132: 589-595.
4. Veeze HJ, Halley DJJ, Bijman J, de Jongste JC, de Jonge HR, Sinaasappel M,. Determinants of mild clinical symptoms in cystic fibrosis patients-residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994; 93: 461-466.
5. - channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004; 127: 1085-1095.
6. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M, Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-635.
7. Castellani C, Cuppens H, Macek M, Jr., Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7: 179-196.
8. Goubau C, Wilschanski M, Skalická V, Lebecque P, Southern KW, Sermet I, Munck A, Derichs N, Middleton PG, Hjelte L, et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 2009; 64: 683-691.
9. Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC,. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981; 124: 484-490.
10. Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17: 1208-1215.
11. Wilschanski M, Dupuis A, Ellis L, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Resp Crit Care Med 2006; 174: 787-794.
12. Mall M, Bleich M, Kuehr J, Brandis M, Greger R, Kunzelmann K,. CFTR-mediated inhibition of epithelial Na+ conductance in human colon is defective in cystic fibrosis. Am J Physiol 1999; 277: G709-G716.
13. Mall M, Bleich M, Schurlein M, Kuehr J, Seydewitz HH, Brandis M, Greger R, Kunzelmann K,. Cholinergic ion secretion in human colon requires coactivation by cAMP. Am J Physiol 1998; 275: G1274-G1281.
14. Veeze HJ, Sinaasappel M, Bijman J, Bouquet J, de Jonge HR,. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 1991; 101: 398-403.
15. Hug M, Tümmler B,. Intestinal current measurements to diagnose cystic fibrosis. J Cyst Fibros 2004; 3: 157-158.
16. Mall M, Wissner A, Seydewitz HH, Kuehr J, Brandis M, Greger R, Kunzelmann K,. Defective cholinergic Cl(-) secretion and detection of K(+) secretion in rectal biopsies from cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2000; 278: G617-G624.
17. Mall M, Hirtz S, Gonska T, Kunzelmann K,. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros 2004; 3: 165-169.
18. Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tümmler B, Gallati S, Ballmann M,. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010; 65: 594-599.
19. Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge HR, Laabs U, Halley DJ, Ellemunter H, Mastella G, Thomas S, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 2001; 108: 1705-1715.
20. Sloane PA, Rowe SM,. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med 2010; 16: 591-597.
21. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-1807.
22. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-35085.
23. Quint A, Lerer I, Sagi M, Abeliovich D,. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am J Med Genet Part A 2005; 136A: 246-248.
24. Laufer-Cahana A, Lerer I, Sagi M, Rachmilewitz-Minei T, Zamir C, Rivlin JR, Abeliovich D,. Cystic fibrosis mutations in Israeli Arab patients. Hum Mutat 1999; 14: 543.
25. Sinaasappel M, Veeze HJ, De Jonge HR,. New insights into the pathogenesis of cystic fibrosis. Scand J Gastroenterol 1990; 178: 17-125.
26. Hug MJ, Derichs N, Bronsveld I, Clancy JP,. Measurement of ion transport function in rectal biopsies. In:, Amaral MD, Kunzelmann K, editors. Cystic fibrosis-diagnosis and protocols. Volume I: approaches to study and correct CFTR defects. New York: Springer Science + Business media, LLC; 2011. pp 87-107.
27. Farrell PM,. The meaning of early diagnosis in a new era of cystic fibrosis care. Pediatrics 2007; 119: 156-157.
28. Lai HJ, Cheng Y, Farrell PM,. The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation Registry Data. J Pediatr 2005; 147: S57-S63.
29. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough. J Pediatr 2005; 147: S30-S36.
30. Narzi L, Terraguti G, Stamato A, Narzi F, Valentini SB, Lelli A, Delaroche I, Lucarelli M, Strom R, Quattrucci S,. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up. Clin Genet 2007; 72: 39-46.
31. Cohen-Cymberknoh M, Shoseyov D, Kerem E,. Managing Cystic Fibrosis: Strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011; 183: 1463-1471.
32. Boyle MP,. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003; 9: 498-503.
33. Wallis C,. Atypical cystic fibrosis-diagnostic and management dilemmas. J R Soc Med 2003; 96: 2-10.
34. Bronsveld I,. Methods of nasal potential difference and intestinal current measurement. In:, Bronsveld I, editor. Modifying factors of cystic fibrosis disease. Rotterdam, The Netherlands: Optima Grafische Communicatie; 2000. pp 63-67.
35. Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH, Amaral MD, Mall MA,. The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS ONE 2011; 6: e24445.